reason report
transform deal close updat model pt
close global strateg collabor mp
cover geoffrey porg previous announc octob
see take-away note updat bgne
model incorpor amgn three late stage product xgeva kyproli
blincyto plu kra inhibitor china
addit oncolog asset bgne pipelin well
equiti invest partial off-set commit
importantli believ strateg collabor meaning diversifi
bgne pipelin provid strong valid bgne differenti
clinic commerci infrastructur china well catapult
compani onto global stage receiv global econom
oncolog pipelin product co-develop reiter
op rate model updat result non-materi chang
price target move pt prior also
reflect share dilut post deal price target
materi chang due increas share count assess
risk-adjust npv bgne asset exclud residu cash
increas
bgne establish global strateg collabor
develop commerci amgn oncolog asset china
specif bgne respons commerci xgeva
kyproli blincyto china bgne option retain product
sale right indefinit one product right second
product revert back five year right third
product revert seven year follow transit back
beigen elig receiv tier mid-singl low-doubl digit
royalti china sale addit five year bgne
collabor global develop oncolog
pipelin product bgne respons conduct develop
activ china two compani co-fund develop cost
bgne contribut beigen receiv tier mid-
singl digit royalti net sale product global outsid
china exclud pipelin drug approv china
beigen right commerci product seven year
econom right retain total six
product indefinit pipelin product transit
back beigen elig tier royalti mid-singl
low-doubl digit net sale china addit five year
also part collabor made equiti invest
ownership stake bgne
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil bgne
compani inform svb leerink llc research
revenu million
pleas refer page import disclosur price chart analyst certif
updat bgne model reflect product china access
oncolog pipelin signific equiti invest
leverag svb leerink ex-u forecast kyproli
xgeva blincyto forecast geoffrey porg well
assumpt drug sale potenti china
bgne commerci drug china believ revenu could
 prior estim china sale base compani strong
commerci track record bristol celgen revlimid abraxan
vidaza assum net profit margin appli
profit/loss share split bgne result
risk-adjust npv bgne commerci asset
kra program addit includ
risk-adjust npv addit earli pipelin asset beyond
oncolog develop portfolio view global
access oncolog portfolio significantli diversifi bgne
pipelin could account anoth fundament valu
total risk-adjust npv bgne earli pipelin
discoveri platform final updat model reflect
equiti invest partial off-set
develop commit increas oper expens go
forward overal updat result new pt non-materi
chang prior target
rate beigen bgne share outperform pt beigen commerci stage
biotechnolog compani number commerci drug licens celgen market
china approv btk inhibitor brukinsa well pipelin development
asset brukinsa zanubrutinib differenti btk inhibitor develop b-cell
malign recent receiv fda approv treatment r/r mantl cell lymphoma
mcl target b-cell pathway btk drug transform chronic lymphocyt
leukemia cll diseas patient die caus rather
malign howev toler issu often result patient stop therapi ibrutinib
beigen brukinsa appear much larger therapeut window fewer advers
event see drug multi-blockbust asset beigen also develop
antibodi tislelizumab purport benefit maintain higher resist
mechan allow tumor circumv blockad given drug modifi fc
region impact role macrophag resist third prong beigen
invest thesi deriv parp inhibitor opportun gastric cancer one
think larg ignor investor follow disappoint class ovarian
cancer well fail lynparza trial gastric cancer drug subtherapeut
dose still provid signal activ importantli beigen forefront chines
biotechnolog effort believ compani like signific home player
advantag versu multi-n corpor china thesi support
global oncolog develop deal includ equiti stake bgne
provid access three commerci product develop stage compound provid
signific valid beigen stori view
updat bgne model reflect deal pt
upon close deal updat bgne model reflect
commerci amgn product china access amgn oncolog pipelin
commit equiti invest leverag svb leerink ex-u forecast
ns kyproli xgeva blincyto forecast geoffrey porg well
assumpt drug sale potenti china base compani strong
commerci track record bristol celgen revlimid abraxan vidaza
appli sale multipli prior estim china sale assum net profit
margin appli profit/loss share bgne profit split
lead risk-adjust npv bgne
addit also includ risk-adjust npv addit pipelin
asset beyond amgn oncolog develop portfolio two compani
collabor global develop asset bgne respons develop
china econom compani global specif bgne co-fund
develop cost bgne contribut beigen receiv tier mid-
singl digit royalti net sale product global outsid china exclud
pipelin drug approv china beigen right commerci
product seven year econom right retain total six
product indefinit pipelin product transit back beigen
elig tier royalti mid-singl low-doubl digit percent net sale china
addit five year pipelin product includ collabor deal rang across
varieti hematolog solid tumor type target modal includ amgn bispecif
cell engag bite half-lif extend bite asset well six preclin asset
disclos believ access amgn oncolog portfolio diversifi
bgne pipelin therapeut geograph assign fundament
valu asset result total risk-adjust npv bgne earli
pipelin discoveri platform
final incorpor equiti invest equiti stake
bgne equiti invest remov financi overhang fund compani
pipelin develop infrastructur build also increas forecast
oper expens go forward clinic develop well increas sg cog
expens support commerci model bgne contribut
co-fund clinic develop amgn oncolog asset number year
specif account commit assum spend spread
sever year gradual increas initi total commit
total commit assumpt lead npv
 commit given estim cash balanc ye assign residu
cash bgne share model chang result new pt prior
use risk-adjust sum-of-the-part methodolog valu beigen deriv pt
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens risk-adjust sum-of-the-part analysi
appli discount rate cash flow gener beigen asset
determin total net present valu risk-adjust asset total npv reflect
remain clinic regulatori risk program
clinic risk clinic trial failur beigen pipelin asset especi later stage
drug includ zanubrutinib tislelizumab pamiparib
commerci risk greater anticip competit either domest china
intern could impact perceiv valu beigen pipelin
regulatori risk failur obtain regulatori approv compani product unit
state europ china would like diminish valu beigen pipelin
productpeak revenu mn phase developmentnpv bgne mn probabl successrisk-adjust npv mn expect launchnet current valu share us/eu zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk tislelizumab tislelizumab pamiparib parp pamiparib parp ovarian product china product china pipelin drug discoveri asset count risk-adjust equiti valu risk zanubrutinib btk cllchina zanubrutinib btk cllus/eu zanubrutinib btk mclus/eu zanubrutinib btk wmus/eu zanubrutinib btk mzlchina zanubrutinib btk mcl/mzl/wmus/eu zanubrutinib btk flchina zanubrutinib btk flus/eu tislelizumab revenuechina tislelizumab revenueww pamiparib parp gastricchina pamiparib parp ovarian cancercelgen product china collaborationamgen product china collaborationearli pipelin drug discoveri platformresidu beigen ltd
companyprogram/drugtherapeut areaeventtimingev typetri phasebeigenezanubrutinibwaldenstrom sdata pivot phii china trial china nda trial dataphiibeigenetislelizumabhepatocellular carcinomaphii data tislelizumab global trial r/r trial dataphiibeigenetislelizumabnon-smal cell lung cancertoplin data phiii china trial non-squam trial dataphiiibeigenetislelizumabnon-smal cell lung cancertoplin data phiii china trial squamou trial dataphiiibeigenetislelizumabbladd cancerpotenti chines approv r/r bladder cancer cancerpivot phii china data ovarian trial dataphiibeigenezanubrutiniblymphomapotenti chines approv r/r mcl r/r lymphocyt leukemiadata phiii sequoia trial zanubrutinib vs br tn cll patient inelig trial dataphiiibeigenezanubrutinibfollicular lymphomadata phii pivot trial gazyva /- zanubrutinib r/r trial dataphiiibeigenepamiparibgastr cancerdata phiii mainten trial pamiparib platinum sensit gastric trial dataphiiibeigenepamiparibovarian cancerdata phiii mainten trial pamiparib plat sensit ovarian cancer trial dataphiiibeigenetislelizumabesophag carcinomadata phiii trial tislelizumab vs physician choic chemo esophag trial dataphiiibeigenetislelizumabnon-smal cell lung cancerdata phiii trial tislelizumab vs docetaxel trial dataphiiibeigenetislelizumabhepatocellular carcinomadata phiii trial tislelizumab vs nexavar trial dataphiiibeigen catalyst beigen ltd
beigen mn except ep
amort intang asset
net loss attribut non-controlling interest
net incom loss attribut bgne
bs cf mn
